XNCR News and Press, Xencor Inc. From 11/08/23

2023-11-08 15:07:59 ET More on Xencor Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor GAAP EPS of -$0.40 beats by $0.31, revenue of $...

2023-11-08 08:29:03 ET Xencor, Inc. (XNCR) Q3 2023 Earnings Conference Call November 7, 2023 16:30 ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer Nancy Valente -...

2023-11-07 16:39:19 ET More on Xencor Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor finance chief to step down Vir Biotech nabs $50M BARDA funding to discover antibody therapies ...

-- Royalty Transaction Generates $215 Million Upfront -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris ®...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Xencor Inc. (XNCR) is expected to report $-0.77 for Q3 2023

2023-11-06 13:53:32 ET Xencor ( NASDAQ: XNCR ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, after market close. The consensus EPS Estimate is -$0.71 and the consensus Revenue Estimate is $30.03M (+10.0% Y/Y). Over the last 3 months, EPS estima...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb ® programs at the 38th Annual Meeting of the Society for I...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. ...